Skip to main content
Caplight Logo









BrainXell

BrainXell

Private
Madison, WisconsinHealthcare & Life Scienceshttps://brainxell.com/

Last Round

Grant

Aug 8, 2023

Total Funding Raised

$19.66M

Company Overview

BrainXell is a biotechnology company that manufactures customized nervous system cells derived from human stem cell lines for use in research and drug discovery.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

iPSC-derived neuronsiPSCscell therapydisease modelingdrug discovery toolsneuroscience researchdirected differentiationiPSC-derived gliaregenerative medicinecellular modelspatient-derived iPSCscustom cell differentiationassay servicesinduced pluripotent stem cellstoxicology screening

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BrainXell Comparables

Compare BrainXell with similar companies based on industry and business-model similarity.

BrainXell comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
iXCells Biotechnologies
88%
NeuCyte
87%
Axol Bioscience
86%

BrainXell Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 8, 2023
Series BSep 28, 2021
AcceleratorNov 1, 2016
GrantSep 1, 2016

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 8, 2025

    Monthly visitors increased 49% MoM, reaching 4K.

  • May 2, 2025

    Monthly visitors increased 35% to 2.3K.

Recent news

Latest coverage and updates

  • is_developingJun 16, 2026

    BrainXell, Inc. is developing New Approach Methodology platforms on Jun 16th '26.

  • is_developingJun 16, 2026

    BrainXell, Inc. is developing integrated platforms that better capture the complexity of the human central nervous system on Jun 16th '26.

BrainXell Filings

Explore SEC and related filing metadata, where available.

BrainXell filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about BrainXell's valuation, stock price, and market status.

Is BrainXell a public or private company?

BrainXell is a private company.

What is the current stock price of BrainXell?

BrainXell is a private company with no public stock price. No recent secondary market data is available.

How much is BrainXell worth (valuation)?

Valuation information for BrainXell is not publicly available.

Can I buy BrainXell stock?

BrainXell shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was BrainXell's last funding round?

BrainXell's most recent funding round was Grant on August 8, 2023.

Who are the main investors in BrainXell?

Key investors in BrainXell include NIH RADx, Wisconsin Economic Development Corporation, WARF Ventures, Discovery to Product, California Institute for Regenerative Medicine.

Will BrainXell IPO soon?

No public IPO plans have been announced for BrainXell.

How can I track BrainXell secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BrainXell's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMadison, Wisconsin
Employee Range32
Year Founded2015
Last FundingAug 8, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?